Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

GA-binding protein α/β is a critical regulator of the BRCA1 promoter

Oncogene volume 19, pages 1933–1940 (2000)Cite this article

Abstract

Decreased expression of BRCA1 may play a role in the etiology of sporadic breast cancer. Deletion and point mutant analysis of proximal promoter elements in the BRCA1 1a promoter revealed a 22 bp region which was critical for the expression of the promoter in MCF-7 cells, but had a much reduced effect in T47D cells. The main transcription factor interacting with this site was identified as GABPα/β, and a discrete DNA binding complex was only observed in nuclear extracts from MCF-7 cells. Cotransfection experiments with GABPα and β1 expression vectors produced transactivation of this element in both lines. These results suggest that GABPα/β is a critical activator of BRCA1 expression, and that its activity may differ in human breast cell lines.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Armstrong SA, Barry DA, Leggett RW and Mueller CR . 1997 J Biol Chem 272: 13489–13495

  • Baert JL, Monte D, Musgrove EA, Albagli O, Sutherland RL and de Launoit Y . 1997 Int J Cancer 70: 590–597

  • Boccia LM, Lillicrap DP, Newcombe K and Mueller CR . 1996 Mol Cell Biol 16: 1929–1935

  • Brown MA, Xu CF, Nicolai H, Griffiths B, Chambers JA, Black D and Solomon E . 1996 Oncogene 12: 2507–2513

  • Casey G . 1997 Curr Opin Oncol 9: 88–93

  • Catteau A, Harris WH, Xu CF and Solomon E . 1999 Oncogene 18: 1957–1965

  • de la Brousse FC, Birkenmeier EH, King DS, Rowe LB and McKnight SL . 1994 Genes Dev 8: 1853–1865

  • Dobrovic A and Simpfendorfer D . 1997 Cancer Res 57: 3347–3350

  • Favy DA, Rio P, Maurizis JC, Hizel C, Bignon YJ and Bernard-Gallon DJ . 1999 Biochem Biophys Res Commun 258: 284–291

  • Fromm L and Burden SJ . 1998 Genes Dev 12: 3074–3083

  • Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barret JC, Skolnick MH, Kamp A and Wiseman R . 1994 Science 266: 120–122

  • Gudas JM, Li T, Nguyen H, Jensen D, Rauscher FJ and Cowan KH . 1996 Cell Growth Differ 7: 717–723

  • Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J and Mak TW . 1996 Cell 85: 1009–1023

  • Hoare S, Copland JA, Wood TG, Jeng YJ, Izban MG and Soloff MS . 1999 Endocrinology 140: 2268–2279

  • Jarvis EM, Kirk JA and Clarke CL . 1998 Cancer Gene Cytogen 101: 109–115

  • Khurana TS, Rosmarin AG, Shang J, Krag TO, Das S and Gammeltoft S . 1999 Mol Biol Cell 10: 2075–2086

  • Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR and Futreal PA . 1996 Nature Genet 13: 238–240

  • Lane TF, Deng C, Elson A, Lyu MS, Kozak CA and Leder P . 1995 Genes Dev 9: 2712–2722

  • Liu CY, Flesken-Nikitin A, Li S, Zeng Y and Lee WH . 1996 Genes Dev 10: 1835–1843

  • Magdinier F, Ribieras S, Lenoir GM, Frappart L and Dante R . 1998 Oncogene 17: 3169–3176

  • Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W and Archer TK . 1998 Oncogene 16: 1161–1169

  • Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA and Iglehart JD . 1997 Oncogene 14: 115–121

  • Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL and Chodosh LA . 1995 Nature Gen 11: 17–26

  • Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C and Frank TS . 1995 Nature Genet 9: 439–443

  • Miki Y, Katagiri T, Kasumi F, Yoshimoto T and Nakamura Y . 1996 Nature Genet 13: 245–247

  • Nuchprayoon I, Simkevich CP, Luo M, Friedman AD and Rosmarin AG . 1997 Blood 89: 4546–4554

  • Ozcelik H, To MD, Couture J, Bull SB and Andrulis II . 1998 Int J Cancer 77: 1–6

  • Rice JC, Massey-Brown KS and Futscher BW . 1998 Oncogene 17: 1807–1812

  • Rio PG, Maurizis JC, Peffault dL, Bignon YJ and Bernard-Gallon DJ . 1999 Int J Cancer 80: 823–826

  • Sawa C, Goto M, Suzuki F, Watanabe H, Sawada J-I and Hanada H . 1996 Nucleic Acids Res 24: 4954–4961

  • Scott GK, Daniel JC, Xiong X, Maki RA, Kabat D and Benz CC . 1994 J Biol Chem 269: 19848–19858

  • Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, Davis T, Ha PC, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AK and Kamb A . 1996 Nature Genet 13: 241–244

  • Thakur S and Croce CM . 1999 J Biol Chem 274: 8837–8843

  • Thompson ME, Jensen RA, Obermiller PS, Page DL and Holt JT . 1995 Nature Genet 9: 444–450

  • Tzahar E and Yarden Y . 1998 Biochim Biophys Acta 1377: M25–M37

  • Virbasius J, Virbasius C and Scarpulla R . 1993 Genes Dev 7: 380–392

  • Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ and Slamon DJ . 1999 Nature Genet 21: 236–240

  • Xu CF, Brown MA, Chambers JA, Griffiths B, Nicolai H and Solomon E . 1995 Human Mol Genet 4: 2259–2264

  • Xu CF, Brown MA, Nicolai H, Chambers JA, Griffiths BL and Solomon E . 1997a Human Mol Genet 6: 1057–1062

  • Xu CF, Chambers JA and Solomon E . 1997b J Biol Chem 272: 20994–20997

  • Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A and Deng CX . 1999 Nature Genet 22: 37–43

  • Yokomori N, Tawata M, Saito T, Shimura H and Onaya T . 1998 Mol Endocrinol 12: 1241–1249

Download references

Acknowledgements

This work was supported by a grant from the Canadian Breast Cancer Research Initiative. Additional support came from Cancer Care Ontario and the Queen's University Faculty of Medicine. We would like to thank Steve McKnight for the gift of the mouse GABP cDNAs and Drs J-I Sawada and H Hanada for the human GABP monoclonal antibodies.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Cancer Research Laboratories, Queen's University, Kingston, K7L 3N6, Ontario, Canada

    Ella Atlas, Melissa Stramwasser, Karen Whiskin & Christopher R Mueller

Authors
  1. Ella Atlas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa Stramwasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen Whiskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher R Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atlas, E., Stramwasser, M., Whiskin, K. et al. GA-binding protein α/β is a critical regulator of the BRCA1 promoter. Oncogene 19, 1933–1940 (2000). https://doi.org/10.1038/sj.onc.1203516

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203516

Keywords

This article is cited by

Search

Advanced search

Quick links